Business
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021. Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25th, 2021 to discuss financial results and provide a business update. Conference Call Information: Date: Thursday, February 25, 2021Time: 8:30 am Eastern TimeDomestic Dial-in: 877-423-9813International Dial-in: 201-689-8573Conference ID: 13716171Webcast: http://public.viavid.com/index.php?id=143423 About Altimmune Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com. Investor & Media Contacts: Will BrownStacey JurchisonChief Financial Officer Sr. Dir, Investor RelationsPhone: 240-654-1450 Phone : 410-474-8200 [email protected] [email protected] \nSource: Altimmune, Inc.","length":3218,"tagName":"div"}]